Acutis Diagnostics recognized by Newsday as a New York success story.

In early December, Acutis was the subject of a feature article by James T, Madore, who writes about Long Island business for NewsdayThe piece describes our work, our rapid growth, and also our plans to expand our current competencies. In the piece, Acutis is described as a “great success story.” As a company in motion and as one committed to the medical community and the public its serves, everyone at Acutis is happy to share this story with you,

A clinical laboratory involved in the fight against opioid addiction and misuse of antibiotics wants to quadruple its space by moving west, from Suffolk County to Nassau, executives said.Acutis Diagnostics Inc., begun three years ago, has grown from two employees working in 1,000 square feet of space in Farmingdale to more than 100 in 10,000 square feet in East Northport. And the company now is looking to buy a 40,000-square-foot building in Hicksville to meet increased demand for its lab tests. CEO Jibreel Sarij said recently that the opioid crisis has fueled sales of Acutis’ medication monitoring systems by physicians, drug treatment centers and others.

Read more

Aetna selects Acutis as an in-network provider

We are pleased to announce that as of October 1, 2018, Aetna — a Fortune 500 Company that has been described by the New York Times as “one of the most progressive actors
in corporate America” — has accepted Acutis as a national, in-network provider.  

aetan-acutis2.jpg

Acutis maintains its commitment to its clients and the industry with:

  1. A no-compromise work ethic that adheres to protocols that have no tolerance for error. 

  2. Our proprietary 728 Patient Report™ that enables clinical decisions by pointing out abuse of prescription/illicit drugs that are too often missed by providers.

  3. A sense of urgency — 97% of our reports are delivered by the next business day.

  4. A payor-centric approach that believes good healthcare delivered at the lowest cost is a business imperative. 

  5. An adherence to “medical necessity” as the only basis for testing, which leads to better patient outcomes with minimal testing.

Only a few, select clinical toxicology laboratories have been accepted as Aetna in-network providers. We see our acceptance as an affirmation, not only for Acutis as a whole, but of every single member of our company, from our PhDs to our support staff. We are honored to have earned Aetna’s trust and will work hard and smart to keep it.

“We will continue to refine our science and technology to ensure greater accuracy and consistency, as well as regular cost savings and rapid turn-around time.
What’s more, our ongoing investment in research and development will lead to greater advancements in clinical toxicology, as well as state-of-the-art diagnostic tests in infectious disease and molecular diagnostics.”
— Jibreel Sarij, Acutis’ CEO

Acutis is on it. Our Sales Specialists Stephen Dybalski and Kseniya Shyrokava were on hand at the 2018 New York & New Jersey Societies of Interventional Pain Physicians’ Pain Medicine Symposium

icone-conference-nov8.jpg

The theme of this year’s show “Evolving Advanced Pain Therapies” could not be more relevant in light of the current opioid and pain-management crises. Nor could it be a more appropriate venue for Acutis to share with this community our new definition of care: A company at the leading edge of medical diagnostics. A company committed to ensure professionals in this specialty have one less thing to worry about.

Led by Chairman, Sudhir Diwan, MD, and Course Directors, Scott Woska, MD and Christopher Gharibo, MD. The show provided the most up-to-date information on advanced pain management techniques, pharmacology, neurostimulation, vertebroplasty, kyphoplasty, discography as well as other treatments and procedures.

Both Stephen and Kseniya made a special point to visit with our current pain-management clients who were in attendance, as well as introduce potential clients to Acutis’ expanding capabilities. New contacts were cultivated and, as important, new lessons were learned that will be shared throughout the entire Acutis network.

During the show Stephen and Kseniya became acquainted with those new products and procedures that were most exciting to members of the medical community. Of particular interest were training geared for primary caregivers, as well as medical-management physicians who require specific training in the prescribing and utilization of opioids and controlled substances.

500 specialists in pain and interventional pain management, as well as neurosurgery were in attendance. Acutis is proud to have been among this esteemed company.

Acutis Steps Up at the 19th Annual ASAP Conference

From September 23rd through the 27th 2018,  CEO Jibreel Sarij and Sales Specialists Jared Blais and Emily Talarico attended the Alcoholism and Substance Abuse Providers of New York State (ASAP) Annual Conference in Syracuse, New York. 

ASAP-website.jpg

That we’re in the midst of a crisis is not news. All attendees at the ASAP Conference are acutely aware of the enormity of the problem. Ben Walsh, the Mayor of Syracuse, mentioned in his remarks that a death by an overdose occurred only a few days earlier, a block from the conference center. Everyone, from caseworkers and administrators, to medical practitioners and specialists, had their war stories. There was no shortage of tactics and strategies discussed, all focused on ASAP’s guiding principle that addiction is a treatable and preventable disease.

A highlight of the conference was a talk by the journalist Sam Quinones, author of the National Book Critics Circle Award-winning book, Dreamland: The True Take of America’s Opiate Epidemic. Quinones took on one of the most controversial issues of the day: how heroin moved from the urban centers into our nation’s heartland.

During the event, Jibreel Sarij spoke at length with ASAP’s Executive Director John Coppola, The two discussed how the ASAP might tap into Acutis’ expertise in drug testing and also how the ASAP might benefit from access to vast amounts of data Acutis has compiled. Coppola accepted an invitation to visit our facility.

We look forward to new friends and a dynamic collaboration.

Visit the 19th Annual ASAP Conference website.

Just don’t call it weed

In early July, the U.S. Food and Drug Administration approved Epidiolex® (cannabidiol or CBD), an oral solution derived from marijuana, for the treatment of two severe pediatric seizure disorders. Epidiolex® is the first, yes, the first, FDA-approved medicine made from a purified extract of the marijuana plant—all natural and nothing synthetic.

Studies have confirmed what has been reported anecdotally about CBD oils—that they are helpful in treating seizures. But stories that circulate like rumors have always been incomplete if not disappointing. That said, starting this autumn, parents whose children suffer from Lennox-Gastaut and Dravet syndromes will have a safer and more reliable treatment than CBD products currently hawked on the Internet or sold in marijuana dispensaries.

article-july23-def4.jpg

FDA approves first drug derived from marijuana.
July 2, 2018

Last week, the Food and Drug Administration(FDA) approved Epidiolex® (cannabidiol, or CBD), a medication extracted from marijuana, for the treatment of two severe pediatric seizure disorders, Lennox-Gastaut syndrome and Dravet syndrome. CBD is a compound typically found in very small quantities in the marijuana plant, and it has been of interest to scientists and the public for several years due to its anti-seizure properties and other possible therapeutic benefits. The approval comes at the end of a four-year series of trials showing the benefits of CBD in relieving the symptoms of these seizure disorders, which are highly resistant to existing treatments.

Lennox-Gastaut and Dravet syndromes are extremely debilitating. Children often suffer multiple seizures per day, they are likely to have developmental problems and are at high risk for early mortality. For several years, desperate parents with children suffering from these disorders sometimes relocated to states where marijuana had been legalized to obtain CBD oils, since this compound had been reported anecdotally to be helpful.

Read the full article online on the National Institute on Drug Abuse (NIDA) website.

Surprising and disturbing

Best business practices require a familiarity with current news. Toward that end, we read industry white papers and university studies, as well as national and local news stories. But familiarity is our point of departure.

News that finds its way into our laboratory will often find its way into our strategies and eventually into new services. Where this particular story leads we can’t say, but as we found it as surprising as it is disturbing, we believe it is worth publishing here.

mussels.jpg

Mussels in Washington's Puget Sound test positive for opioids, other drugs

“Shellfish in the Puget Sound, an inlet of the Pacific Ocean along the northwest coast of Washington, tested positive for the prescription opioid oxycodone... The mussels also contained four kinds of synthetic surfactants -- the chemicals found in detergents and cleaning products -- seven kinds of antibiotics, five types of antidepressants, more than one anti-diabetic drug and one chemotherapy agent.”

“Scientists have not studied whether mussels are harmed by oxycodone. However, the presence of this drug in the mollusk speaks to the high number of people in the urban areas surrounding the Puget Sound who take this medication, said Lanksbury.”

"We decided it was important for us to start looking for 'contaminants of emerging concern,' " she said. This term refers to pharmaceuticals and personal care products -- including prescription drugs, detergents, shampoos and micro-plastic beads -- that are increasingly being detected in waterways, such as the Puget Sound.

A study conducted by the US Geological Survey found measurable amounts of one or more medications in 80% of the water samples drawn from 139 streams in 30 states.”

Follow this and related stories:

Expectations met at ICCO 2018

boston.jpg

Acutis Diagnostics’ Charlie Clark and Chuck Orefice attended the International Conference on Opioids, at the Joseph B. Martin Conference Center at Harvard Medical School in Boston, Massachusetts, held from June 10th - 12th, 2018.

We came with high expectations for this meeting, especially in light of the current crisis. We were not disappointed. Thought leaders and practitioners from the U.S. and abroad addressed topics of increasing urgency, from the best emerging medical practices using opioid to treat pain, to the rapidly evolving ethical and legal aspects of opioid management.

Acutis Diagnostics is intimately familiar with the challenges faced by physicians who seek greater clarity and new competences. Toward that end, we were excited to learn new concepts and applications in medication monitoring and illicit drug testing. We will continue to hone our science and services with a single goal in mind: reduce risk to both practitioners and patients, while improving clinical outcomes.

Fentanyl-laced heroin overdoses rise California signaling higher need for clinical caution

Sans titre-14.jpg

The CDC reports that opioids of all types have killed more than 33,000 people in 2015 alone, and the number is rising. A newer threat of mixed opioids plagues Ventura County in California and could signal a need for more caution across the country.

Ventura County has reported a rise in fatal opioid overdoses that could be attributed to the spread of heroin laced with fentanyl. “People are using these drugs expecting one result and getting a much more potent result, a result that can end up with death,” says Dr. Robert Levin, a physician and public health officer in the county. The public health officials of the county note that opiates can be accessed very easily, sometimes by mail order, and that there is very little oversight in the mixes of opioids that people are purchasing illegally.

Some forms of synthetic opioids are significantly easier to produce and sell illegally than are others. Carfentanyl and fentanyl are both extremely potent in small quantities and present an extreme health risk as a result. Synthetic opioids as a whole have caused 72.2% more deaths from 2014 to 2015, according to the CDC. The CDC also reports that the rates at which confiscated drugs testing positive for fentanyl are growing faster than prescription rates. This indicates that synthetic opioids like fentanyl are further infiltrating the street and illicit drug use scene.

It is the mixing of synthetic opioids with heroin that is most troubling, especially for Ventura County. Fentanyl is a synthetic opioid that is 50 to 100 times more potent than morphine. Heroin, in comparison, is two to four times as potent as morphine, according to a research article in the Journal of Pharmacology and Experimental Therapeutics. Mixing fentanyl and heroin can easily produce an opioid dose that exceeds the potency of safely prescribed amounts of opioids by several orders of magnitude.

What can be done about this problem?

Ultimately, opioid dependence and addiction must be resolved under supervision of a qualified health provider. A core component of any addiction or dependence treatment program is toxicology-based monitoring for compliance and for metrics. Acutis Diagnostics is a New York toxicology lab that works closely with the medical and patient community to ensure safe, healthy, and timely treatment of all disorders, including opioid dependence and addiction. Please contact Acutis Diagnostics to learn how the services offered here can help provide a path to treatment for all patients.

For more information about the recent events in Ventura County, please look at this article by the Ventura County Star.

For more information about fentanyl and to see a wealth of information about the opioid crisis, visit the CDC’s page about fentanyl here.

To read the Journal of Pharmacology and Experimental Therapeutics’ article about equivalent doses of heroin and morphine, please click here.

This article is written by Yusuf Sheth. Yusuf is a Masters of Public Health Candidate at Downstate Medical Center.

Marijuana wins big on election night

Sans titre-9.jpg

Voters in California, Massachusetts and Nevada approved recreational marijuana initiatives Tuesday night, and several other states passed medical marijuana provisions, in what is turning out to be the biggest electoral victory for marijuana reform since 2012, when Colorado and Washington first approved the drug's recreational use.

In addition to the states above, local outlets in Maine are declaring victory for that state's legalization measure, but with 91 percent of precincts reporting just a few thousand votes separate the "Yes" and "No" columns.

A similar legalization measure in Arizona did not gain sufficient support to pass, with 52 percent of voters rejecting it.

On the medical side, voters in Florida, North Dakota and Arkansas have approved medical marijuana initiatives. Voters in in Montana also rolled back restrictions on an existing medical pot law.

Reformers were jubilant. “This represents a monumental victory for the marijuana reform movement,” said Ethan Nadelmann, executive director of the Drug Policy Alliance, in a statement. “With California’s leadership now, the end of marijuana prohibition nationally, and even internationally, is fast approaching.”

California has long been seen as a bellwether by both supporters and opponents of marijuana reform. The state is home to about 12 percent of the U.S. population. Given the size of the state's economy and the economic impact of the marijuana industry there, California's adoption of legal marijuana could prompt federal authorities to rethink their decades-long prohibition on the use of marijuana.

In a recent interview with Bill Maher, President Obama said that passage of the legalization measures on Tuesday could make the current federal approach to the drug “untenable.”

Still, the likelihood of a Trump White House leaves a lot of uncertainty about the fate of marijuana measures in the next four years. Under Obama, federal authorities largely took a hands-off approach to state-level legalization efforts. But an incoming administration more skeptical of drug reform could easily reverse that approach.

“The prospect of Rudy Giuliani or Chris Christie as attorney general does not bode well,” the Drug Policy Alliance's Nadelmann said in an interview. “There are various ways in which a hostile White House could trip things up.”

Nadelmann pointed to the success of marijuana measures in the midst of an evident Republican wave as a sign that support for legalization now cuts deeply across party lines. And citing Trump's often contradictory statements on marijuana and drug use in the past, Nadelmann added that “Donald Trump personally could probably go any which way on this.”

With today's votes, legal marijuana is also making significant inroads in the Northeast. “Marijuana legalization has arrived on the East Coast,” said Tom Angell of the marijuana reform group Marijuana Majority in an email. “What Colorado and other states have already done is generating revenue, creating jobs and reducing crime, so it’s not surprising that voters in more places are eager to end prohibition.”

Opponents of legalization said they were disappointed by the outcomes. “We were outspent greatly in both California and Massachusetts, so this loss is disappointing, but not wholly unexpected,” said Kevin Sabet of the anti-legalization group Smart Approaches to Marijuana in a statement. “Despite having gained considerable ground in the last few weeks, the out-of-state interests determined to make money off of legalization put in too much money to overcome.”

Votes on medical marijuana in Florida and North Dakota were decisive. Florida's Amendment 2 passed with 71 percent support, according to the Associated Press. In North Dakota, the AP reportsthat 64 percent of voters approving of the medical marijuana measure.

Two years ago, a medical marijuana measure in Florida earned 58 percent of the vote, just shy of the 60 percent threshold needed for passage. Then, as now, opposition to the measure was fueled by multimillion-dollar donations from Sheldon Adelson, the Las Vegas casino magnate and GOP donor. In 2014 Adelson spent $5.5 million to defeat the measure. This year he's spent $1.5 million in Florida, and several million more to defeat recreational marijuana measures in other states.

“This is a major tipping point,” said Tom Angell of Florida's vote. “With Florida's decision, a majority of states in the U.S. now have laws allowing patients to find relief with medical marijuana, and these protections and programs are no longer concentrated in certain regions of the country like the West and Northeast.”

The victory in North Dakota is something of a surprise as no polling was done on the measure.

The Florida amendment has the potential to be one of the more permissive medical marijuana regimes in the nation. In addition to diseases like HIV, cancer and PTSD, the measure also allows doctors to recommend medical pot for “other debilitating medical conditions of the same kind or class as or comparable to those enumerated, and for which a physician believes that the medical use of marijuana would likely outweigh the potential health risks for a patient.” While the 2014 measure allowed doctors to prescribe marijuana for any illness they believed it would be useful for, the new measure requires they show the illness is severe — though the wording gives physicians considerable leeway in determining which conditions would meet those criteria.

The medical pot measure in North Dakota allows doctors to recommend the drug for a number of severe medical conditions.

With the passage of Amendment 2, Florida will become the first Southern state to enact a robust medical marijuana regime. Medical marijuana is already legal in 25 other states and the District.

“Better late than never,” said Ethan Nadelmann, executive director of the drug reform group Drug Policy Alliance, in a statement. “Most states outside the South already have legal medical marijuana, but the overwhelming victory today in Florida is likely to accelerate the momentum for reform throughout the region.”

Originally published in the Washington Post.

Fighting the Opioid epidemic from the ground up: Teaching rising medical professionals how to use Naloxone

Sans titre-13.jpg

In April of this year, Wright State University, Ohio was the staging ground for equipping healthcare students to better handle the opioid crisis. A coalition of various local activism and healthcare improvement groups assembled an event to train more than 40 aspiring professionals about how to use naloxone. The group included medical students, healthcare-related undergraduate students, pharmaceutical students, and physician assistant students.

Naloxone, the opioid antagonist used to block the effects of opioids notably in formulations such as Suboxone, has become ubiquitous in the fight against opioid overdose. Law enforcement and other emergency response forces have even begun to train to use it. Naloxone is a critical part of the opioid-dependence treatment. When bundled with buprenorphine in Suboxone, it acts to deter abuse of the opioid while ensuring that the patient does not undergo withdrawal.

The opioid crisis is critically important to healthcare providers today. The CDC reports that 91 Americans die every single day from opioid overdose, including from prescription drugs. Training health practitioners to be able to respond to this is crucial in preventing unnecessary death and getting the proper treatment to these patients.

At Acutis Diagnostics, our goal is to be a clinical tool that ensures the best possible care for the patient. Please visit our testing services page to see how our laboratory can benefit you and your patients: http://www.acutisdiagnostics.com/testing

To read more about the naloxone instruction at Wright University, please see the full article at the Sidney Daily News by following the link below.
https://goo.gl/2FQnQ8